Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Slipek

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|December 14, 2018
CRISPR/Cas9-Based Positive Screens for Cancer-Related TraitsNicholas J Slipek, Jyotika Varshney, David A Largaespada
Biorxiv : the Preprint Server for Biology|September 26, 2025
Installation of Dominant-Negative Mutations in <i>FAS</i> and <i>TGFβR2</i> via Base Editing in Primary T CellsBryce J Wick, Mitchell G Kluesner, Nicholas J Slipek, et al.
Molecular Therapy. Oncology|October 27, 2025
Installation of dominant-negative mutations in <i>FAS</i> and <i>TGFβR2</i> via base editing in primary T cellsBryce J Wick, Mitchell G Kluesner, Nicholas J Slipek, et al.
Journal of Visualized Experiments : Jove|May 26, 2025
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA TemplatesMatthew J Johnson, Anthony P DeFeo, Nicholas J Slipek, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2024
Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage DisordersKanut Laoharawee, Evan W Kleinboehl, Jacob D Jensen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2024
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disordersEvan W Kleinboehl, Kanut Laoharawee, Jacob D Jensen, et al.
Molecular Therapy. Advances|May 25, 2026
Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapyJae-Woong Chang, Joshua Krueger, Timothy D Folsom, et al.
International Journal of Molecular Sciences|September 9, 2022
A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human MonocytesKanut Laoharawee, Matthew J Johnson, Walker S Lahr, et al.
Cytotherapy|July 17, 2025
Clinical manufacture of CRISPR/Cas9-based cytokine-induced SH2 protein knock-out tumor-infiltrating lymphocytes for gastrointestinal cancersMatthew J Johnson, Darin Sumstad, Timothy D Folsom, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base EditingMinjing Wang, Joshua B Krueger, Alexandria K Gilkey, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|December 14, 2018
CRISPR/Cas9-Based Positive Screens for Cancer-Related TraitsNicholas J Slipek, Jyotika Varshney, David A Largaespada
Biorxiv : the Preprint Server for Biology|September 26, 2025
Installation of Dominant-Negative Mutations in <i>FAS</i> and <i>TGFβR2</i> via Base Editing in Primary T CellsBryce J Wick, Mitchell G Kluesner, Nicholas J Slipek, et al.
Molecular Therapy. Oncology|October 27, 2025
Installation of dominant-negative mutations in <i>FAS</i> and <i>TGFβR2</i> via base editing in primary T cellsBryce J Wick, Mitchell G Kluesner, Nicholas J Slipek, et al.
Journal of Visualized Experiments : Jove|May 26, 2025
Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA TemplatesMatthew J Johnson, Anthony P DeFeo, Nicholas J Slipek, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2024
Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage DisordersKanut Laoharawee, Evan W Kleinboehl, Jacob D Jensen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2024
Engineering memory T cells as a platform for long-term enzyme replacement therapy in lysosomal storage disordersEvan W Kleinboehl, Kanut Laoharawee, Jacob D Jensen, et al.
Molecular Therapy. Advances|May 25, 2026
Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapyJae-Woong Chang, Joshua Krueger, Timothy D Folsom, et al.
International Journal of Molecular Sciences|September 9, 2022
A Pan-RNase Inhibitor Enabling CRISPR-mRNA Platforms for Engineering of Primary Human MonocytesKanut Laoharawee, Matthew J Johnson, Walker S Lahr, et al.
Cytotherapy|July 17, 2025
Clinical manufacture of CRISPR/Cas9-based cytokine-induced SH2 protein knock-out tumor-infiltrating lymphocytes for gastrointestinal cancersMatthew J Johnson, Darin Sumstad, Timothy D Folsom, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Precision Enhancement of CAR-NK Cells through Non-Viral Engineering and Highly Multiplexed Base EditingMinjing Wang, Joshua B Krueger, Alexandria K Gilkey, et al.
Pageof 3